Literature DB >> 26945036

Neuronal Injury, Gliosis, and Glial Proliferation in Two Models of Temporal Lobe Epilepsy.

Jaycie L Loewen1, Melissa L Barker-Haliski1, E Jill Dahle1, H Steve White1, Karen S Wilcox2.   

Abstract

It is estimated that 30%-40% of epilepsy patients are refractory to therapy and animal models are useful for the identification of more efficacious therapeutic agents. Various well-characterized syndrome-specific models are needed to assess their relevance to human seizure disorders and their validity for testing potential therapies. The corneal kindled mouse model of temporal lobe epilepsy (TLE) allows for the rapid screening of investigational compounds, but there is a lack of information as to the specific inflammatory pathology in this model. Similarly, the Theiler murine encephalomyelitis virus (TMEV) model of TLE may prove to be useful for screening, but quantitative assessment of hippocampal pathology is also lacking. We used immunohistochemistry to characterize and quantitate acute neuronal injury and inflammatory features in dorsal CA1 and dentate gyrus regions and in the directly overlying posterior parietal cortex at 2 time points in each of these TLE models. Corneal kindled mice were observed to have astrogliosis, but not microgliosis or neuron cell death. In contrast, TMEV-injected mice had astrogliosis, microgliosis, neuron death, and astrocyte and microglial proliferation. Our results suggest that these 2 animal models might be appropriate for evaluation of distinct therapies for TLE.
© 2016 American Association of Neuropathologists, Inc. All rights reserved.

Entities:  

Keywords:  Animal models; Antiseizure drugs; Astrogliosis; Corneal kindling; Microglia; Temporal lobe epilepsy; Theiler murine encephalomyelitis virus (TMEV).

Mesh:

Substances:

Year:  2016        PMID: 26945036      PMCID: PMC5009480          DOI: 10.1093/jnen/nlw008

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  49 in total

1.  Neurotropic viral infections leading to epilepsy: focus on Theiler's murine encephalomyelitis virus.

Authors:  Jane E Libbey; Robert S Fujinami
Journal:  Future Virol       Date:  2011-11       Impact factor: 1.831

Review 2.  The role of inflammation in epilepsy.

Authors:  Annamaria Vezzani; Jacqueline French; Tamas Bartfai; Tallie Z Baram
Journal:  Nat Rev Neurol       Date:  2010-12-07       Impact factor: 42.937

3.  Innate but not adaptive immune responses contribute to behavioral seizures following viral infection.

Authors:  Nikki J Kirkman; Jane E Libbey; Karen S Wilcox; H Steve White; Robert S Fujinami
Journal:  Epilepsia       Date:  2009-10-20       Impact factor: 5.864

4.  All astrocytes are not created equal--the role of astroglia in brain injury.

Authors:  Darcie L Moore; Sebastian Jessberger
Journal:  EMBO Rep       Date:  2013-04-26       Impact factor: 8.807

5.  Regional vulnerability after traumatic brain injury: gender differences in mice that overexpress human copper, zinc superoxide dismutase.

Authors:  T Igarashi; T T Huang; L J Noble
Journal:  Exp Neurol       Date:  2001-12       Impact factor: 5.330

Review 6.  Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs.

Authors:  Wolfgang Löscher
Journal:  Seizure       Date:  2011-02-02       Impact factor: 3.184

7.  Corneal kindling in mice: behavioral and pharmacological differences to conventional kindling.

Authors:  H Potschka; W Löscher
Journal:  Epilepsy Res       Date:  1999-11       Impact factor: 3.045

8.  Theiler's virus infection chronically alters seizure susceptibility.

Authors:  Kerry-Ann A Stewart; Karen S Wilcox; Robert S Fujinami; H Steve White
Journal:  Epilepsia       Date:  2009-12-01       Impact factor: 5.864

Review 9.  Pathogenesis of epilepsy: challenges in animal models.

Authors:  Yow Hui Yin; Nurulumi Ahmad; Mohd Makmor-Bakry
Journal:  Iran J Basic Med Sci       Date:  2013-11       Impact factor: 2.699

Review 10.  Animal models of epilepsy: use and limitations.

Authors:  Ludmyla Kandratavicius; Priscila Alves Balista; Cleiton Lopes-Aguiar; Rafael Naime Ruggiero; Eduardo Henrique Umeoka; Norberto Garcia-Cairasco; Lezio Soares Bueno-Junior; Joao Pereira Leite
Journal:  Neuropsychiatr Dis Treat       Date:  2014-09-09       Impact factor: 2.570

View more
  37 in total

Review 1.  Validated animal models for antiseizure drug (ASD) discovery: Advantages and potential pitfalls in ASD screening.

Authors:  Melissa Barker-Haliski; H Steve White
Journal:  Neuropharmacology       Date:  2019-08-27       Impact factor: 5.250

2.  Positive modulation of mGluR5 attenuates seizures and reduces TNF-α+ macrophages and microglia in the brain in a murine model of virus-induced temporal lobe epilepsy.

Authors:  Tyler J Hanak; Jane E Libbey; Daniel J Doty; Jordan T Sim; Ana Beatriz DePaula-Silva; Robert S Fujinami
Journal:  Exp Neurol       Date:  2018-10-11       Impact factor: 5.330

3.  Evaluation of Cannabidiol in Animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP).

Authors:  Brian D Klein; Catherine A Jacobson; Cameron S Metcalf; Misty D Smith; Karen S Wilcox; Aidan J Hampson; John H Kehne
Journal:  Neurochem Res       Date:  2017-05-06       Impact factor: 3.996

Review 4.  Epilepsy as a Network Disorder (2): What can we learn from other network disorders such as dementia and schizophrenia, and what are the implications for translational research?

Authors:  Helen E Scharfman; Andres M Kanner; Alon Friedman; Ingmar Blümcke; Candice E Crocker; Fernando Cendes; Ramon Diaz-Arrastia; Hans Förstl; André A Fenton; Anthony A Grace; Jorge Palop; Jason Morrison; Astrid Nehlig; Asuri Prasad; Karen S Wilcox; Nathalie Jette; Bernd Pohlmann-Eden
Journal:  Epilepsy Behav       Date:  2017-10-31       Impact factor: 2.937

Review 5.  Strengthening the Case for Epilepsy Drug Development: Bridging Experiences from the Alzheimer's Disease Field-An Opinion.

Authors:  Roy E Twyman
Journal:  Neurochem Res       Date:  2017-06-07       Impact factor: 3.996

6.  CB2R induces a protective response for epileptic seizure via the PI3K 110α-AKT signaling pathway.

Authors:  Qingjun Cao; Xueyan Liu; Fenghua Yang; Hua Wang
Journal:  Exp Ther Med       Date:  2018-09-24       Impact factor: 2.447

7.  Validation of a Preclinical Drug Screening Platform for Pharmacoresistant Epilepsy.

Authors:  Melissa L Barker-Haliski; Kristina Johnson; Peggy Billingsley; Jennifer Huff; Laura J Handy; Rizvana Khaleel; Zhenmei Lu; Matthew J Mau; Timothy H Pruess; Carlos Rueda; Gerald Saunders; Tristan K Underwood; Fabiola Vanegas; Misty D Smith; Peter J West; Karen S Wilcox
Journal:  Neurochem Res       Date:  2017-03-16       Impact factor: 3.996

8.  Acute cognitive impact of antiseizure drugs in naive rodents and corneal-kindled mice.

Authors:  Melissa L Barker-Haliski; Fabiola Vanegas; Matthew J Mau; Tristan K Underwood; H Steve White
Journal:  Epilepsia       Date:  2016-07-28       Impact factor: 5.864

9.  Antiseizure drug efficacy and tolerability in established and novel drug discovery seizure models in outbred vs inbred mice.

Authors:  Zachery Koneval; Kevin M Knox; Ali Memon; Dannielle K Zierath; H Steve White; Melissa Barker-Haliski
Journal:  Epilepsia       Date:  2020-08-05       Impact factor: 5.864

10.  Loss of presenilin 2 age-dependently alters susceptibility to acute seizures and kindling acquisition.

Authors:  Megan Beckman; Kevin Knox; Zachery Koneval; Carole Smith; Suman Jayadev; Melissa Barker-Haliski
Journal:  Neurobiol Dis       Date:  2019-12-17       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.